International Clinical Trial: Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07724457) titled 'Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: National Cancer Institute (NCI)

Condition: Recurrent Burkitt Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements Refractory Burkitt Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements

Intervention: Procedure: Biospecimen Collection Procedure: Bone Marrow ...